{"id":179,"date":"2022-04-05T20:36:27","date_gmt":"2022-04-05T11:36:27","guid":{"rendered":"http:\/\/www.mcl-corp.jp\/meditrans\/?page_id=179"},"modified":"2025-05-14T09:45:52","modified_gmt":"2025-05-14T00:45:52","slug":"samples","status":"publish","type":"page","link":"http:\/\/www.mcl-corp.jp\/meditrans\/samples\/","title":{"rendered":"MediTRANS\u7ffb\u8a33\u30b5\u30f3\u30d7\u30eb"},"content":{"rendered":"\n

\u5404\u5206\u91ce\u306e\u8ad6\u6587\u306e\u7ffb\u8a33\u30b5\u30f3\u30d7\u30eb\u3092\u4ee5\u4e0b\u306b\u7d39\u4ecb\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n\n\n\n

\u3010\u6ce8\u3011MediTRANS\u3067\u306f\u3001PDF\u3067\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9\u3057\u305f\u8ad6\u6587\u306eFullText\u3092\u305d\u306e\u307e\u307e\u7ffb\u8a33\u3059\u308b\u3053\u3068\u304c\u3067\u304d\u307e\u3059\u3002\u305f\u3060\u3001\u8ad6\u6587PDF\u306f\u6bb5\u7d44\u307f\uff08\u30da\u30fc\u30b8\u5185\u3067\u7e26\u306b\u533a\u5207\u3089\u308c\u3066\u3044\u308b\u30ec\u30a4\u30a2\u30a6\u30c8\uff09\u306e\u30ec\u30a4\u30a2\u30a6\u30c8\u306b\u306a\u3063\u3066\u3044\u308b\u3053\u3068\u3082\u591a\u304f\u3001PDF\u30d5\u30a1\u30a4\u30eb\u3092\u305d\u306e\u307e\u307eMediTRANS\u3067\u65e5\u672c\u8a9e\u306b\u7ffb\u8a33\u3057\u305f\u5834\u5408\u306b\u3001\u82f1\u6587\u3068\u548c\u6587\u306e\u9577\u3055\u306e\u9055\u3044\u306a\u3069\u3067\u3001\u65e5\u672c\u8a9e\u30d5\u30a1\u30a4\u30eb\u306e\u30ec\u30a4\u30a2\u30a6\u30c8\u304c\u304b\u306a\u308a\u5d29\u308c\u3066\u3057\u307e\u3046\u3053\u3068\u304c\u3042\u308a\u307e\u3059\u3002\u305d\u306e\u305f\u3081\u4ee5\u4e0b\u306e\u8a33\u6587\u30b5\u30f3\u30d7\u30eb\u3067\u306f\u3001\u8a33\u6587\u81ea\u4f53\u3092\u3054\u89a7\u3044\u305f\u3060\u304d\u3084\u3059\u3044\u3088\u3046\u306b\u30ec\u30a4\u30a2\u30a6\u30c8\u3092\u5c11\u3057\u8abf\u6574\u3057\u305f\u3082\u306e\u3092\u63b2\u8f09\u3044\u305f\u3057\u3066\u304a\u308a\u307e\u3059\uff08\u624b\u9806\u306f\u3053\u3061\u3089<\/a>\u3067\u3054\u89a7\u3044\u305f\u3060\u3051\u307e\u3059\uff09\u3002<\/p>\n\n\n\n

\u25a0COVID19\u95a2\u9023<\/h3>\n\n\n\n
\n

[\u539f\u6587]<\/h4>\n\n\n\n

SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011SARS-CoV-2-antibodies-IgA-JMV-9999<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

SARS-CoV-2\u6297\u4f53:IgA\u306fCOVID-19\u65e9\u671f\u611f\u67d3\u306b\u304a\u3051\u308b\u91cd\u75c7\u5ea6\u3068\u76f8\u95a2<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011SARS-CoV-2-antibodies-IgA-JMV-9999<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\n

[\u539f\u6587]<\/h4>\n\n\n\n

IgA dominates the early neutralizing antibody response to SARS-CoV-2<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011IgA-dominates-the-early-neutralizing-antibody-response-abd2223-1<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

SARS-CoV-2\u306b\u5bfe\u3059\u308b\u65e9\u671f\u4e2d\u548c\u6297\u4f53\u53cd\u5fdc\u306fIgA\u304c\u512a\u52e2\u3067\u3042\u308b<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011IgA-dominates-the-early-neutralizing-antibody-response-abd2223-1<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\n

[\u539f\u6587]<\/h4>\n\n\n\n

Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011Fighting-the-SARS-CoV-2-pandemic-requires-s41590-022-01130-4<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

SARS-CoV-2\u30d1\u30f3\u30c7\u30df\u30c3\u30af\u3068\u306e\u95d8\u3044\u306b\u306f\u3001\u30ef\u30af\u30c1\u30f3\u53cd\u5fdc\u306e\u4e0d\u5747\u4e00\u6027\u3092\u7406\u89e3\u3059\u308b\u305f\u3081\u306e\u4e16\u754c\u7684\u306a\u30a2\u30d7\u30ed\u30fc\u30c1\u304c\u5fc5\u8981\u3067\u3042\u308b<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011Fighting-the-SARS-CoV-2-pandemic-requires-s41590-022-01130-4<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\n

[\u539f\u6587]<\/h4>\n\n\n\n

Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011Efficacy-of-a-Fourth-Dose-of-Covid-19-mRNA-Vaccine-against-Omicron<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

4\u56de\u76ee\u306eCovid-19 mRNA\u30ef\u30af\u30c1\u30f3\u306eOmicron\u306b\u5bfe\u3059\u308b\u52b9\u529b<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011Efficacy-of-a-Fourth-Dose-of-Covid-19-mRNA-Vaccine-against-Omicron<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n<\/div><\/div>\n\n\n\n
\n\n\n\n
\n

[\u539f\u6587]<\/h4>\n\n\n\n

Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011Detection-of-cross-reactive-IgA-against-SARS-CoV-2-spike-1-subunit-in-saliva-pone.0249979<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u553e\u6db2\u4e2d\u306e\u91cd\u75c7\u6025\u6027\u547c\u5438\u5668\u75c7\u5019\u7fa4-\u30b3\u30ed\u30ca\u30a6\u30a4\u30eb\u30b9-2\u30b9\u30d1\u30a4\u30af1\u30b5\u30d6\u30e6\u30cb\u30c3\u30c8\u306b\u5bfe\u3059\u308b\u4ea4\u5dee\u53cd\u5fdc\u6027\u514d\u75ab\u30b0\u30ed\u30d6\u30ea\u30f3A\u306e\u691c\u51fa<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011Detection-of-cross-reactive-IgA-against-SARS-CoV-2-spike-1-subunit-in-saliva-pone.0249979-1<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n<\/div><\/div>\n\n\n\n

\u25a0\u773c\u79d1<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

A randomised, controlled, observermasked trial of corneal cross-linking for progressive keratoconus in children: the KERALINK protocol<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011e028761.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u5c0f\u5150\u306e\u9032\u884c\u6027\u5186\u9310\u89d2\u819c\u306b\u5bfe\u3059\u308b\u89d2\u819c\u30af\u30ed\u30b9\u30ea\u30f3\u30ad\u30f3\u30b0\u306b\u3064\u3044\u3066\u89b3\u5bdf\u8005\u3092\u30de\u30b9\u30af\u3057\u305f\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13:KERALINK\u30d7\u30ed\u30c8\u30b3\u30eb<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011e028761.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u816b\u760d<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011nihms-1761424<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u624b\u8853\u53ef\u80fd\u306a\u975e\u5c0f\u7d30\u80de\u80ba\u764c\u306b\u5bfe\u3059\u308b\u8853\u524d\u88dc\u52a9\u7642\u6cd5\u3068\u3057\u3066\u306e\u30cb\u30dc\u30eb\u30de\u30d6\u307e\u305f\u306f\u30cb\u30dc\u30eb\u30de\u30d6\u3068\u30a4\u30d4\u30ea\u30e0\u30de\u30d6\u306e\u4f75\u7528:\u7b2c2\u76f8\u30e9\u30f3\u30c0\u30e0\u5316\u8a66\u9a13\u3067\u3042\u308bNEOSTAR\u8a66\u9a13<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011nihms-1761424<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n
\n
\n

<\/p>\n<\/div>\n\n\n\n

\n

<\/p>\n<\/div>\n<\/div>\n\n\n\n

\u25a0\u6804\u990a<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Human Postprandial Responses to Food and Potential for Precision Nutrition<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011nihms-1712232<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u98df\u7269\u306b\u5bfe\u3059\u308b\u30d2\u30c8\u306e\u98df\u5f8c\u306e\u53cd\u5fdc\u3068\u7cbe\u5bc6\u6804\u990a\u306e\u53ef\u80fd\u6027<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011nihms-1712232<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u809d\u80c6<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Prostaglandin E2 Mediates Immunosuppression in Acutely Decompensated Cirrhosis<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011emss-72000<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u30d7\u30ed\u30b9\u30bf\u30b0\u30e9\u30f3\u30b8\u30f3E2\u306f\u6025\u6027\u975e\u4ee3\u511f\u6027\u809d\u786c\u5909\u306b\u304a\u3051\u308b\u514d\u75ab\u6291\u5236\u3092\u5a92\u4ecb\u3059\u308b<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011emss-72000<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u7b4b\u9aa8\u683c<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Soft drink intake and progression of radiographic knee osteoarthritis: data from the osteoarthritis initiative<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011e002993.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u30bd\u30d5\u30c8\u30c9\u30ea\u30f3\u30af\u306e\u6442\u53d6\u304a\u3088\u3073X\u7dda\u753b\u50cf\u4e0a\u306e\u5909\u5f62\u6027\u819d\u95a2\u7bc0\u75c7\u306e\u9032\u884c:
\u5909\u5f62\u6027\u95a2\u7bc0\u75c7\u306b\u95a2\u3059\u308b\u53d6\u308a\u7d44\u307f\u306e\u30c7\u30fc\u30bf<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011e002993.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

<\/p>\n\n\n\n

\u25a0\u8840\u6db2<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u301141591_2021_Article_1436<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u518d\u767a\u307e\u305f\u306f\u96e3\u6cbb\u6027\u306eB\u7d30\u80de\u60aa\u6027\u816b\u760d\u306e\u6210\u4eba\u60a3\u8005\u306b\u304a\u3044\u3066CD19\u304a\u3088\u3073CD22\u3092\u4e8c\u91cd\u6a19\u7684\u3068\u3059\u308bCAR-T\u7d30\u80de:\u7b2cI\u76f8\u8a66\u9a13<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u301141591_2021_Article_1436<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u7523\u5a66\u4eba\u79d1<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Association between vitamin D and uterine fibroids: a study protocol of an open-label, randomised controlled trial<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011e038709.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u30d3\u30bf\u30df\u30f3D\u3068\u5b50\u5bae\u7b4b\u816b\u3068\u306e\u95a2\u9023:\u975e\u76f2\u691c\u30e9\u30f3\u30c0\u30e0\u5316\u6bd4\u8f03\u8a66\u9a13\u306e\u8a66\u9a13\u5b9f\u65bd\u8a08\u753b\u66f8<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011e038709.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u6d88\u5316\u7ba1<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011457.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

Helicobacter pylori\u611f\u67d3\u75c7\u306f\u304c\u3093\u514d\u75ab\u7642\u6cd5\u306e\u52b9\u529b\u306b\u6709\u5bb3\u306a\u5f71\u97ff\u3092\u53ca\u307c\u3059<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011457.full_<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u5fc3\u8840\u7ba1<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011cir-144-1196<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u51fa\u8840\u30ea\u30b9\u30af\u304c\u9ad8\u3044\u60a3\u8005\u306b\u304a\u3051\u308b\u7d4c\u53e3\u5264\u4f75\u7528\u307e\u305f\u306f\u975e\u4f75\u7528\u3067\u306e\u6297\u8840\u5c0f\u677f\u7642\u6cd5\u306e\u77ed\u7e2e\u51a0\u52d5\u8108\u30b9\u30c6\u30f3\u30c8\u7559\u7f6e\u5f8c\u306e\u6297\u51dd\u56fa\u7642\u6cd5<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011cir-144-1196<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u795e\u7d4c\u5185\u79d1<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011s41591-021-01556-7<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

COVID-19\u30ef\u30af\u30c1\u30f3\u304a\u3088\u3073SARS-CoV-2\u306e1\u56de\u76ee\u306e\u63a5\u7a2e\u5f8c\u306b\u751f\u3058\u305f\u795e\u7d4c\u7cfb\u5408\u4f75\u75c7<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011s41591-021-01556-7<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

\u25a0\u5185\u5206\u6ccc<\/h3>\n\n\n\n

[\u539f\u6587]<\/h4>\n\n\n\n

Decreased SIRT1 expression in the peripheral
blood of patients with Graves\u2019 disease<\/p>\n\n\n\n

<\/object>\u3010\u539f\u6587\u3011JOE-19-0501<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n\n\n\n

[\u8a33\u6587]<\/h4>\n\n\n\n

\u30b0\u30ec\u30fc\u30f4\u30b9\u75c5\u60a3\u8005\u306e\u672b\u68a2\u8840\u306b\u304a\u3051\u308bSIRT1\u767a\u73fe\u306e\u6e1b\u5c11<\/p>\n\n\n\n

<\/object>\u3010\u8a33\u6587\u3011JOE-19-0501<\/a>\u30c0\u30a6\u30f3\u30ed\u30fc\u30c9<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

\u5404\u5206\u91ce\u306e\u8ad6\u6587\u306e\u7ffb\u8a33\u30b5\u30f3\u30d7\u30eb\u3092\u4ee5\u4e0b\u306b\u7d39\u4ecb\u3044\u305f\u3057\u307e\u3059\u3002 \u3010\u6ce8\u3011MediTRANS\u3067\u306f<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":15,"comment_status":"closed","ping_status":"closed","template":"templates\/front-page.php","meta":[],"_links":{"self":[{"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/pages\/179"}],"collection":[{"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/comments?post=179"}],"version-history":[{"count":27,"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/pages\/179\/revisions"}],"predecessor-version":[{"id":1633,"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/pages\/179\/revisions\/1633"}],"wp:attachment":[{"href":"http:\/\/www.mcl-corp.jp\/meditrans\/wp-json\/wp\/v2\/media?parent=179"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}